BRAF and non-small cell lung carcinoma: Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From <i>EGFR</i>-Mutant NSCLC With Acquired <i>BRAF</i> V600E Mutation: A Case Report.